Trastuzumab deruxtecan

Pre-clinicalCompleted

0 views this week 0 watching💤 Quiet

Interest: 26/100

Hype Score

Development Stage

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

HER2-positive Breast Cancer

Conditions

HER2-positive Breast Cancer

Trial Timeline

Nov 11, 2022 → Dec 1, 2023

NCT ID

NCT05458401

About Trastuzumab deruxtecan

Trastuzumab deruxtecan is a pre-clinical stage product being developed by Daiichi Sankyo for HER2-positive Breast Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT05458401. Target conditions include HER2-positive Breast Cancer.

What happened to similar drugs?

0 of 15 similar drugs in HER2-positive Breast Cancer were approved

Approved (0) Terminated (0) Active (15)

🔄TrastuzumabCelltrionPhase 3

🔄Trastuzumab + Pertuzumab + Docetaxel + Paclitaxel + Nab-paclitaxel + Vinorelbine + Eribulin + Capecitabine + GemcitabineChugai PharmaceuticalPhase 3

🔄Trastuzumab deruxtecan + Placebo + Taxane + Pertuzumab + TrastuzumabDaiichi SankyoPhase 3

🔄DS-8201a + T-DM1Daiichi SankyoPhase 3

🔄SHR-A1811 Injection + SHR-A1811 Injection ； Pertuzumab Injection + Trastuzumab Injection；Pertuzumab Injection ； Docetaxel InjectionJiangsu Hengrui MedicinePhase 3

🔄SHR-A1811 for Injection + Docetaxel injection + Trastuzumab Injection + Carboplatin for Injection + Pertuzumab InjectionJiangsu Hengrui MedicinePhase 3

🔄Pyrotinib + Placebo Oral Tablet + Trastuzumab + DocetaxelJiangsu Hengrui MedicinePhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (19)

NCT ID	Phase	Status	Start	Completion	Indication
NCT07015697	Phase 1	Recruiting	Jul 17, 2025	Dec 31, 2028	Recurrent or Metastatic Solid Tumors
NCT06750484	Phase 2	Recruiting	Jun 20, 2025	Dec 31, 2028	Breast Cancer Metastatic
NCT05982678	Phase 2	Recruiting	May 2, 2024	Oct 1, 2034	HER2-positive Breast Cancer
NCT06386263	Pre-clinical	Completed	Apr 22, 2024	Jul 7, 2025	Unresectable Breast Cancer
NCT06210776	Pre-clinical	Recruiting	Jan 15, 2024	Mar 1, 2028	HER2-positive Breast Cancer
NCT05950945	Phase 3	Recruiting	Dec 30, 2023	Oct 1, 2027	Breast Cancer
NCT05993234	Pre-clinical	Recruiting	Dec 5, 2023	Sep 1, 2027	HER2-positive Advanced Gastric Cancer
NCT05945732	Pre-clinical	Recruiting	Oct 24, 2023	Sep 1, 2028	Unresectable Breast Cancer
NCT05458401	Pre-clinical	Completed	Nov 11, 2022	Dec 1, 2023	HER2-positive Breast Cancer
NCT05246514	Phase 2	Active	Jul 13, 2022	Mar 16, 2026	HER2-mutant Non-Small Cell Lung Cancer
NCT04989816	Phase 2	Completed	Aug 20, 2021	Feb 28, 2024	Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
NCT04739761	Phase 3	Active	Jun 22, 2021	May 26, 2026	Breast Cancer
NCT04644237	Phase 2	Completed	Mar 19, 2021	Aug 23, 2024	Non-Small Cell Lung Cancer
NCT04639219	Phase 2	Active	Dec 30, 2020	Jul 14, 2026	Advanced Solid Tumors With HER2 Mutation,eg:Colorectal,Urothelial,Gastric, Hepatobiliary,Endometrial,Melanoma,Ovarian,Cervical,Salivary Gland,Pancreatic,Breast
NCT04482309	Phase 2	Recruiting	Aug 18, 2020	Jul 30, 2027	Part 1: Bladder, Biliary Tract, Cervical, Endometrial, Ovarian, Pancreatic Cancer, Rare Tumors, Any Tumor Type Excluding Breast, Gastric, Colorectal Cancer
NCT04752059	Phase 2	Completed	Jul 28, 2020	May 1, 2023	Breast Cancer Stage IV
NCT04420598	Phase 2	Completed	May 25, 2020	Apr 4, 2023	Advanced Breast Cancer
NCT04014075	Phase 2	Completed	Nov 26, 2019	Feb 13, 2024	Adenocarcinoma Gastric Stage IV With Metastases
NCT03505710	Phase 2	Terminated	May 21, 2018	Apr 17, 2024	Non-Small Cell Lung Cancer

Competing Products

20 competing products in HER2-positive Breast Cancer

See all competitors

Product	Company	Stage	Hype Score
ALT-P7 (HM2-MMAE)	Alteogen	Phase 1	29
CT-0508 + Pembrolizumab	Carisma Therapeutics	Phase 1	23
CT-0525	Carisma Therapeutics	Phase 1	23
Trastuzumab	Celltrion	Phase 3	40
Trastuzumab + Pertuzumab + Docetaxel + Paclitaxel + Nab-paclitaxel + Vinorelbine + Eribulin + Capecitabine + Gemcitabine	Chugai Pharmaceutical	Phase 3	40
YH32367	Yuhan	Phase 1/2	39
Trastuzumab deruxtecan	Daiichi Sankyo	Pre-clinical	33
Trastuzumab deruxtecan	Daiichi Sankyo	Pre-clinical	33
Trastuzumab deruxtecan (T-DXd)	Daiichi Sankyo	Pre-clinical	33
Trastuzumab deruxtecan	Daiichi Sankyo	Phase 2	42
Trastuzumab deruxtecan + Placebo + Taxane + Pertuzumab + Trastuzumab	Daiichi Sankyo	Phase 3	44
DS-8201a + T-DM1	Daiichi Sankyo	Phase 3	44
Pertuzumab + Trastuzumab + eribulin	Eisai	Phase 2	27
Tucatinib 150 MG + Trastuzumab + Capecitabine	Biocon	Phase 2	42
SHR-A1811 Injection + SHR-A1811 Injection ； Pertuzumab Injection + Trastuzumab Injection；Pertuzumab Injection ； Docetaxel Injection	Jiangsu Hengrui Medicine	Phase 3	44
Pyrotinib	Jiangsu Hengrui Medicine	Pre-clinical	22
SHR-A1811 for Injection + Docetaxel injection + Trastuzumab Injection + Carboplatin for Injection + Pertuzumab Injection	Jiangsu Hengrui Medicine	Phase 3	47
Pyrotinib + Placebo Oral Tablet + Trastuzumab + Docetaxel	Jiangsu Hengrui Medicine	Phase 3	40
SHR-A1811 + Ramucirumab / Paclitaxel/ Docetaxel/ Irinotecan	Jiangsu Hengrui Medicine	Phase 3	47
pyrotinib tablet + Montmorillonite Power + Loperamide	Jiangsu Hengrui Medicine	Phase 1	29